Breaking News

Financial Report: AMRI 3Q

November 6, 2012

Large-scale manufacturing revenue up 14%


3Q Revenues: $55.8 million (+11%)
3Q Loss: $2.1 million (loss of $5.9 million 3Q11)
YTD Revenues: $159.5 million (-1%)
YTD Loss:
$5.7 million (loss of $7.9 million YTD11)
Total contract revenue for the quarter was $45.6 million, up 4%. Large Scale manufacturing revenue was $29.3 million (+14%). Discovery Services revenue was flat at $8.9 million. Development/Small-Scale Manufacturing revenue was $7.4 million (-20%). Royalty revenue in the quarter was $9.4 million (+45%) related to worldwide sales of Allegra, and certain generic forms of Allegra. Revenue in the quarter includes milestones totaling $0.8 million from the company’s 2005 licensing agreement with BMS.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks